- Home
- SB vs SAGE Comparison
SB vs SAGE Comparison
Compare SB & SAGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SB
- SAGE
- Stock Information
- Founded
- SB 2007
- SAGE 2010
- Country
- SB Monaco
- SAGE United States
- Employees
- SB N/A
- SAGE N/A
- Industry
- SB Marine Transportation
- SAGE Biotechnology: Pharmaceutical Preparations
- Sector
- SB Consumer Discretionary
- SAGE Health Care
- Exchange
- SB Nasdaq
- SAGE Nasdaq
- Market Cap
- SB 379.0M
- SAGE 444.1M
- IPO Year
- SB 2008
- SAGE 2014
- Fundamental
- Price
- SB $3.73
- SAGE $7.31
- Analyst Decision
- SB Strong Buy
- SAGE Hold
- Analyst Count
- SB 1
- SAGE 20
- Target Price
- SB $6.00
- SAGE $10.67
- AVG Volume (30 Days)
- SB 697.1K
- SAGE 1.8M
- Earning Date
- SB 02-18-2025
- SAGE 02-11-2025
- Dividend Yield
- SB 5.36%
- SAGE N/A
- EPS Growth
- SB 36.11
- SAGE N/A
- EPS
- SB 0.83
- SAGE N/A
- Revenue
- SB $307,633,000.00
- SAGE $41,243,000.00
- Revenue This Year
- SB $6.30
- SAGE $123.13
- Revenue Next Year
- SB N/A
- SAGE $69.65
- P/E Ratio
- SB $4.49
- SAGE N/A
- Revenue Growth
- SB 8.17
- SAGE N/A
- 52 Week Low
- SB $3.31
- SAGE $4.62
- 52 Week High
- SB $6.33
- SAGE $23.22
- Technical
- Relative Strength Index (RSI)
- SB 56.90
- SAGE 60.55
- Support Level
- SB $3.62
- SAGE $7.00
- Resistance Level
- SB $3.77
- SAGE $7.26
- Average True Range (ATR)
- SB 0.13
- SAGE 0.19
- MACD
- SB 0.02
- SAGE -0.06
- Stochastic Oscillator
- SB 60.61
- SAGE 57.14
About SB Safe Bulkers Inc ($0.001 par value)
Safe Bulkers Inc is an international provider of marine drybulk transportation services, transporting bulk cargoes, particularly coal, grain and iron ore, along international shipping routes for consumers of marine drybulk transportation services. The company employs its vessels on both period time charters and spot time charters, according to the assessment of market conditions, with consumers of marine drybulk transportation services.
About SAGE Sage Therapeutics Inc.
Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on brain health medicines. The company is targeting diseases and disorders of the brain with three key focus areas: depression, neurology and neuropsychiatry; also targeting two critical central nervous system, or CNS, receptor systems, GABA and NMDA. Its products ZURZUVAE is a medicine for the treatment of postpartum depression, or PPD, in adults, and ZULRESSO is a CIV injection for the treatment of postpartum depression in individuals 15 years old and older. It also has other drugs in its pipeline such as SAGE-324, Dalzanemdor (SAGE-718) among others.